Novacyt (CHIX:NCYTL) GF Score: 18/100 (As of Aug. 03, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:NCYTL Novacyt SA CHIX:NCYTL
18 GF Score
Price £0.38
GF Value £0.66
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Novacyt GF Score?

Novacyt CHIX:NCYTL 18 GF Score is 18 as of Aug. 03, 2026, which is at its 10-year median of 18.00. GuruFocus rates CHIX:NCYTL with a GF Score™ of 18/100 and a GF Value™ of £0.66 (Possible Value Trap). The stock has 4 warning signs investors should review.

Novacyt has the GF Score of 18, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 1/10
3. Growth Rank : 1/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Novacyt might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Novacyt  (CHIX:NCYTl) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Novacyt GF Score Related Terms

CHIX:NCYTL vs ABT, SYK, MDT: GF Score Comparison

For the Medical Devices subindustry, Novacyt's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novacyt GF Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Novacyt's GF Score distribution charts can be found below:

* The bar in red indicates where Novacyt's GF Score falls into.


CHIX:NCYTL
18GF Score
Novacyt SA CHIX:NCYTL
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 18 mean?
Novacyt (CHIX:NCYTL) has a GF Score of 18 as of Aug. 03, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Novacyt and its competitors. This is near median its historical median of 18.00. Over the past decade, Novacyt's GF Score has ranged from 13.00 to 21.00.
Is Novacyt's GF Score too high?
Novacyt's current GF Score of 18 is near median its 10-year median of 18.00. Over the past 10 years, this metric has ranged from a low of 13.00 to a high of 21.00. Overall, Novacyt has a GF Score™ of 18/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Novacyt's GF Score compare to ABT and SYK?
Novacyt's GF Score of 18 can be compared against companies in the Medical Devices & Instruments industry. Historically, Novacyt's own GF Score has ranged from 13.00 to 21.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Novacyt and its competitors. Novacyt's current GF Score is 18, which is near median its own 10-year median of 18.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novacyt stock overvalued right now?
Based on GuruFocus' analysis, Novacyt (CHIX:NCYTL) is currently considered Possible Value Trap. The stock's GF Value™ is £0.66, compared to a current price of £0.38 — trading 43.2% below its estimated fair value. The current GF Score is 18, which is near median its 10-year median of 18.00. Novacyt's overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Novacyt (CHIX:NCYTL), the current GF Score is 18 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novacyt (CHIX:NCYTL) Overvalued in 2026?

Based on GuruFocus' analysis, Novacyt stock appears to be undervalued. The current stock price of £0.38 is trading 43.2% below its estimated GF Value™ of £0.66. GuruFocus considers Novacyt to be Possible Value Trap.

Key valuation signals for CHIX:NCYTL:

  • GF Score: 18 (near median its 10-year median of 18.00)
  • GF Value™: £0.66 vs. price of £0.38 (43.2% below fair value)
  • GF Score™: 18/100 with 4 warning signs

No single metric tells the full story. See the CHIX:NCYTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novacyt Business Description

Address 131 Boulevard Carnot, Le Vesinet, FRA, 78110
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, Yourgene Health and Corporate. Majority of the revenue is generated from Yourgene Health segment. Geographically, the company operates in United Kingdom, France, Europe, America, Asia-Pacific, Middle East and Africa generating majority from Asia- pacific region.
18GF Score

Get the complete analysis for CHIX:NCYTL

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.38
Price
£0.66
GF Value